SLDB
$7.76
Solid Biosciences Inc.
Intraday
Recent News
Solid Biosciences says interim results reinforce confidence in SGT-003 potential
Solid Biosciences (SLDB) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomarker, cardiac function, and safety analyses, “add to a growing dataset that suggests the potential of the biological activity of SGT-003 microdystrophin therapy,” the company stated. The interim update was delivered in an oral presentation at the 2026 MDA Annual Meeting on March 11. “SGT-003 has been
Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks
Today, March 11, 2026, Oracle’s earnings beat and solid inflation data stand out as U.S. stocks wobble on oil and war fears.
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences (NASDAQ:SLDB) used a presentation at the 2026 Emerging Outlook Biotech Summit to outline its gene therapy-focused pipeline and discuss recent regulatory interactions around its lead Duchenne muscular dystrophy (DMD) program, SGT-003, as well as early progress in Friedreich’s ataxia
Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope.
Sarepta Therapeutics stock jumped after the company unveiled positive top-line results for a study measuring the efficacy of Elevidys, its controversial blockbuster treatment for Duchenne muscular dystrophy. Patients in the study showed “statistically significant, clinically meaningful and durable efficacy across all key motor function measures” three years after treatment, Sarepta said. The mean North Star Ambulatory Assessment score, a 17-item scale that grades functional motor abilities in patients, remained above baseline for the treated group, while the external control group “continued to show the expected age-related decline below their baseline score,” Sarepta said.
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.